Wall Street analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to announce earnings of ($0.80) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Coherus Biosciences’ earnings. The lowest EPS estimate is ($0.82) and the highest is ($0.77). Coherus Biosciences posted earnings per share of ($1.09) during the same quarter last year, which indicates a positive year over year growth rate of 26.6%. The business is expected to issue its next earnings report on Monday, November 5th.

On average, analysts expect that Coherus Biosciences will report full-year earnings of ($3.05) per share for the current year, with EPS estimates ranging from ($3.07) to ($3.03). For the next fiscal year, analysts expect that the business will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.04) to ($1.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Coherus Biosciences.

Coherus Biosciences (NASDAQ:CHRS) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04).

CHRS has been the subject of a number of recent research reports. ValuEngine raised shares of Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Maxim Group set a $18.00 price objective on shares of Coherus Biosciences and gave the stock a “buy” rating in a research note on Thursday, May 3rd. BidaskClub raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Finally, Zacks Investment Research downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, May 8th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Coherus Biosciences has a consensus rating of “Buy” and an average price target of $25.20.

NASDAQ:CHRS traded down $0.10 during trading hours on Monday, reaching $18.90. The company’s stock had a trading volume of 206,621 shares, compared to its average volume of 416,672. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -4.22 and a beta of 3.68. Coherus Biosciences has a 12 month low of $8.05 and a 12 month high of $19.60. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 1.66.

In other news, insider Barbara K. Finck sold 1,760 shares of the company’s stock in a transaction on Monday, June 18th. The stock was sold at an average price of $15.00, for a total transaction of $26,400.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jean-Frederic Viret sold 9,291 shares of the company’s stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $18.56, for a total value of $172,440.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,571 shares of company stock worth $258,734. Insiders own 26.28% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp increased its position in shares of Coherus Biosciences by 5.3% during the second quarter. Bank of New York Mellon Corp now owns 186,287 shares of the biotechnology company’s stock worth $2,608,000 after purchasing an additional 9,299 shares in the last quarter. Orbimed Advisors LLC increased its position in shares of Coherus Biosciences by 0.9% during the second quarter. Orbimed Advisors LLC now owns 1,480,482 shares of the biotechnology company’s stock worth $20,727,000 after purchasing an additional 13,682 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Coherus Biosciences during the second quarter valued at $118,000. Marshall Wace LLP purchased a new stake in shares of Coherus Biosciences during the second quarter valued at $369,000. Finally, Macquarie Group Ltd. grew its holdings in shares of Coherus Biosciences by 3.1% during the second quarter. Macquarie Group Ltd. now owns 433,000 shares of the biotechnology company’s stock valued at $6,062,000 after buying an additional 13,000 shares during the last quarter. 82.70% of the stock is currently owned by institutional investors and hedge funds.

About Coherus Biosciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Featured Story: What is a Tariff?

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.